Aspirin therapy in aspirin-exacerbated respiratory disease: A risk-benefit analysis for the practicing allergist

Allergy and Asthma Proceedings

Volumn 32, Issue 5, 2011, Pages 335-340

  Baker, Troy W ^a   Quinn, James M ^a  

^a WILFORD HALL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CORTICOSTEROID DERIVATIVE; ESOMEPRAZOLE; HISTAMINE H2 RECEPTOR ANTAGONIST; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT; PROTON PUMP INHIBITOR; SUCRALFATE;

ANGIONEUROTIC EDEMA; ASPIRIN EXACERBATED RESPIRATORY DISEASE; ASTHMA; DIGESTIVE SYSTEM ULCER; DRUG DOSE INCREASE; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG MEGADOSE; DUODENUM ULCER; DYSPEPSIA; GASTROINTESTINAL DISEASE; HEALTH CARE PERSONNEL; HELICOBACTER INFECTION; HUMAN; MYALGIA; PROPHYLAXIS; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; STOMACH ULCER; TINNITUS; URTICARIA;

ASPIRIN; DESENSITIZATION, IMMUNOLOGIC; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TRACT; HUMANS; MUCOUS MEMBRANE; RESPIRATORY HYPERSENSITIVITY; RISK ASSESSMENT; RISK FACTORS;

EID: 80053430060     PISSN: 10885412     EISSN: 15396304     Source Type: Journal    
DOI: 10.2500/aap.2011.32.3457     Document Type: Review

References (47)

1. Wolff T, Miller T, and Ko S. Aspirin for the primary prevention of cardiovascular events: An update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 150:405-410, 2009.
2. Laine L. Review article: Gastrointestinal bleeding with lowdose aspirin - What's the risk? Aliment Pharmacol Ther 24:897-908, 2006. (Pubitemid 44326371)
3. Hope AP, Woessner KA, Simon RA, et al. Rational approach to aspirin dosing during oral challenges and desensitization of patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 123:406-410, 2009.
4. Stevenson DD. Aspirin sensitivity and desensitization for asthma and sinusitis. Curr Allergy Asthma Rep 9:155-163, 2009.
5. Stevenson DD, and Simon RA. Selection of patients for aspirin desensitization treatment. J Allergy Clin Immunol 118:801-804, 2006. (Pubitemid 44498748)
6. Gomes E, Cardoso MF, Praça F, et al. Self-reported drug allergy in a general adult Portuguese population. Clin Exp Allergy 34:1597-1601, 2004. (Pubitemid 39389338)
7. Hedman J, Kaprio J, Poussa T, et al. Prevalence of asthma, aspirin intolerance, nasal polyposis and chronic obstructive pulmonary disease in a population-based study. Int J Epidemiol 28:717-722, 1999. (Pubitemid 29401332)
8. Vally H, Taylor ML, and Thompson PJ. The prevalence of aspirin intolerant asthma (AIA) in Australian asthmatic patients. Thorax 57:569-574, 2002. (Pubitemid 34761756)
9. Kasper L, Sladek K, Duplaga M, et al. Prevalence of asthma with aspirin hypersensitivity in the adult population of Poland. Allergy 58:1064-1066, 2003. (Pubitemid 37260352)
10. Berges-Gimeno MP, Simon RA, and Stevenson DD. Long-term treatment with aspirin desensitization in asthmatic patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 111:180-186, 2003. (Pubitemid 36143311)
11. Stevenson DD, Hankammer MA, Mathison DA, et al. Aspirin desensitization treatment of aspirin-sensitive patients with rhinosinusitis- asthma: Long-term outcomes. J Allergy Clin Immunol 98:751-758, 1996. (Pubitemid 26357241)
12. Rozsasi A, Polzehl D, Deutschle T, et al. Long-term treatment with aspirin desensitization: A prospective clinical trial comparing 100 and 300 mg aspirin daily. Allergy 63:1228-1234, 2008.
13. Rao P, and Knaus EE. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): Cyclooxygenase (COX) inhibition and beyond. J Pharm Pharm Sci 11:81s-110s, 2008.
14. Whittle BJ, and Moncada S. Pharmacological interactions between prostacyclin and thromboxanes. Br Med Bull 39:232-238, 1983. (Pubitemid 13063951)
15. Needleman P, and Isakson PC. The discovery and function of COX-2. J Rheumatol Suppl 49:6-8, 1997.
16. Wolfe MM, Lichtenstein DR, and Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 340:1888-1899, 1999. (Pubitemid 29272670)
17. vane JR, and Botting RM. The mechanism of aspirin. Thromb Res 110:255-588, 2003.
18. Armstrong CP, and Blower AL. Non-steroidal anti-inflammatory drugs and life threatening complications of peptic ulceration. Gut 28:527-532, 1987. (Pubitemid 17073216)
19. Singh G, Ramey DR, Morfeld D, et al. Gastrointestinal tract complications of nonsteroidal anti-inflammatory drug treatment in rheumatoid arthritis. A prospective observational cohort study. Arch Intern Med 156:1530-1536, 1996.
20. Fries JF, Williams CA, Bloch DA, et al. Nonsteroidal anti-inflammatory drug-associated gastropathy: Incidence and risk factor models. Am J Med 91:213-222, 1991.
21. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: Results of a double-blind outcomes study in patients with rheumatoid arthritis. Gastroenterology 123:1006-1012, 2002.
22. Griffin MR, Piper JM, Daugherty JR, et al. Nonsteroidal antiinflammatory drug use and increased risk for peptic ulcer disease in elderly persons. Ann Intern Med 114:257-263, 1991.
23. Chey WD, and Wong BC. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 102:1808-1825, 2007. (Pubitemid 47206706)
24. Chan FKL, Chung SCS, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacterpylori Infection who are taking low-dose aspirin or naproxen. N Engl J Med 344:967-973, 2001. (Pubitemid 32240315)
25. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 343:834-839, 2000.
26. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med 325: 1261-1266, 1991.
27. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 143:1-13, 1996. (Pubitemid 26402780)
28. McQuaid KR, and Laine L. Systematic review and meta-analysis of adverse events of low-dose aspirin and clopidogrel in randomized controlled trials. Am J Med 119:624-638, 2006. (Pubitemid 44128438)
29. Derry S, and Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: Meta-analysis. BMJ 11:1183-1187, 2000.
30. Lee JY, Simon RA, and Stevenson DD. Selection of aspirin dosages for aspirin desensitization treatment in patients with aspirin-exacerbated respiratory disease. J Allergy Clin Immunol 119:157-164, 2007. (Pubitemid 46037806)
31. Scarpignato C, Pelosini I, and Di Mario F. Acid suppression therapy: Where do we go from here? Dig Dis 24:11-46, 2006.
32. Yeomans N, Angel L, Joachim L, et al. Efficacy of esomeprazole (20 mg once daily) for reducing the risk of gastroduodenal ulcers associated with continuous use of low-dose aspirin. Am J Gastroenterol 103:2465-2473, 2008.
33. Bianchi Porro G, Lazzaroni M, Imbesi V, et al. Efficacy of pantoprazole in the prevention of peptic ulcers, induced by non-steroidal anti-inflammatory drugs: A prospective, placebocontrolled, double-blind, parallel-group study. Dig Liver Dis 32:201-208, 2000. (Pubitemid 30345348)
34. Graham DY, Agrawal NM, Campbell DR, et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: Results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med 162:169-175, 2002. (Pubitemid 34098186)
35. Labenz J, Petersen KU, Rösch W, et al. A summary of Food and Drug Administration-reported adverse events and drug interactions occurring during therapy with omeprazole, lansoprazole and pantoprazole. Aliment Pharmacol Ther 17:1015-1019, 2003.
36. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 123:241-249, 1995.
37. Hawkey CJ, Karrasch JA, Szczepanski L, et al. Omeprazole compared with misoprostol for ulcers associated with non-steroidal antiinflammatory drugs. N Engl J Med 338:727-734, 1998. (Pubitemid 28115091)
38. Raskin JB, White RH, Jaszewski R, et al. Misoprostol and ranitidine in the prevention of NSAID-induced ulcers: A prospective, double-blind, multicenter study. Am J Gastroenterol 91: 223-227, 1996. (Pubitemid 126734008)
39. Rostom A, Dube C, Wells GA, et al. Prevention of NSAIDinduced gastroduodenal ulcers. Cochrane Database Syst Rev 4:CD002296, 2002.
40. Ligumsky M, Karmeli F, and Rachmilewitz D. Sucralfate protection against gastrointestinal damage: Possible role of prostanoids. Isr J Med Sci 22:801-806, 1986. (Pubitemid 17017211)
41. Agrawal NM, Roth S, Graham DY, et al. Misoprostol compared with sucralfate in the prevention of nonsteroidal anti-inflammatory drug-induced gastric ulcer. A randomized, controlled trial. Ann Intern Med 115:195-200, 1991.
42. Lanza F, Peace K, Gustitus L, et al. A blinded endoscopic comparative study of misoprostol versus sucralfate and placebo in the prevention of aspirin-induced gastric and duodenal ulceration. Am J Gastroenterol 83:143-146, 1988.
43. Kelly JP, Kaufman DW, Jurgelon JM, et al. Risk of aspirinassociated major upper-gastrointestinal bleeding with entericcoated or buffered product. Lancet 348:1413-1416, 1996. (Pubitemid 26395236)
44. Lanza FL. Endoscopic evaluation of the effects of aspirin, buffered aspirin, and enteric-coated aspirin on gastric and duodenal mucosa. N Engl J Med 303:136-138, 1980. (Pubitemid 10076606)
45. Petroski D. Endoscopic comparison of three aspirin preparations and placebo. Clin Ther 15:314-320, 1993. (Pubitemid 23168494)
46. Lanza FL, Francis KLC, and Eamonn MMQ. Guidelines for prevention of NSAID-related ulcer complications. Am J Gastroenterol 104:728-738, 2009.
47. Brown TJ, Hooper L, Elliott RA, et al. A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: A systematic review with economic modeling. Health Technol Assess 10:1-183, 2006.